· clinical-corner · 9 min read
Mechanism, weight loss, A1C, cardiovascular and kidney outcomes, dosing structure, supply, pricing dynamics — a clean 2026 side-by-side for the two molecules that defined the incretin era.
Semaglutide and tirzepatide are the two molecules that defined the modern incretin era. Semaglutide is a pure GLP-1 receptor agonist; tirzepatide is a dual GIP/GLP-1 receptor agonist. As of mid-2026, both have multiple FDA approvals, both have read out on cardiovascular and renal endpoints, and both are increasingly competing on the same indications. This is a clean side-by-side for researchers and clinicians.
Both compounds act on incretin receptors that mediate post-prandial insulin release, gastric emptying, and central appetite signaling. Tirzepatide adds GIP receptor agonism on top of GLP-1, which appears to amplify weight loss and metabolic benefit relative to GLP-1 alone. See our semaglutide profile and tirzepatide profile for sequence-level detail.
| Property | Semaglutide | Tirzepatide |
|---|---|---|
| Class | GLP-1 RA | GIP/GLP-1 dual RA |
| Manufacturer | Novo Nordisk | Eli Lilly |
| Approved as | Ozempic, Wegovy, Rybelsus | Mounjaro, Zepbound |
| Route | SC weekly, oral daily (Rybelsus) | SC weekly |
| Half-life | ~7 days | ~5 days |
| First FDA approval | 2017 (Ozempic, T2D) | 2022 (Mounjaro, T2D) |
The clearest head-to-head dataset is SURMOUNT-5, a 72-week randomized trial that compared maximum-tolerated tirzepatide versus maximum-tolerated semaglutide in adults with obesity. Tirzepatide produced more weight loss and more responders at the ≥15% threshold. For dosing structure, see our tirzepatide reconstitution calculator and semaglutide reconstitution calculator.
| Endpoint | Semaglutide 2.4 mg | Tirzepatide 15 mg |
|---|---|---|
| Mean weight loss at ~72 weeks | ~15% | ~21% |
| ≥15% weight loss responders | ~50% | ~70% |
| A1C reduction (T2D, head-to-head SURPASS-2) | ~1.8% | ~2.3% |
| Direct head-to-head (obesity, SURMOUNT-5) | Reference arm | Statistically superior |
| Cardiovascular outcomes confirmed | Yes (SUSTAIN-6, SELECT) | SURPASS-CVOT readout pending |
Both molecules now have data well beyond their original indications. SELECT (semaglutide) established MACE reduction in non-diabetic patients with established CV disease. SUMMIT (tirzepatide) showed benefit in HFpEF with obesity. SYNERGY-NASH (tirzepatide) and ESSENCE (semaglutide) addressed MASH. FLOW (semaglutide) showed renal benefit in T2D with CKD. See our clinical trials tracker for the full readout calendar.
| Indication | Semaglutide | Tirzepatide |
|---|---|---|
| Type 2 diabetes | Approved | Approved |
| Chronic weight management | Approved | Approved |
| MACE reduction in CVD + obesity | Approved (SELECT) | Pending (SURPASS-CVOT) |
| Heart failure (HFpEF + obesity) | STEP-HFpEF (positive) | SUMMIT (positive) |
| MASH | ESSENCE (positive Ph3) | SYNERGY-NASH (positive Ph2) |
| CKD in T2D | FLOW (positive) | Not yet |
| Obstructive sleep apnea + obesity | Not yet | SURMOUNT-OSA (approved indication) |
| Alzheimer's disease | EVOKE / EVOKE+ ongoing | Not yet |
Both classes share the same dominant side-effect profile: nausea, vomiting, constipation, and early-treatment GI distress that improves with slow titration. Discontinuation rates in trials are broadly similar across the two molecules; real-world adherence is shaped more by titration support and supply than by inherent tolerability differences.
Both molecules came off the FDA drug-shortage list. Compounded semaglutide and tirzepatide have been pushed out of the legal U.S. supply for most patients except where a personalized clinical need is documented. List prices remain high in the U.S.; international markets vary widely. See the regulation tracker for ongoing updates.
| Factor | Semaglutide (Novo) | Tirzepatide (Lilly) |
|---|---|---|
| FDA shortage list status | Resolved | Resolved |
| Legal 503A compounding | Restricted | Restricted |
| Direct-to-patient program | NovoCare | LillyDirect |
| Generic timeline (U.S.) | Late 2030s (patents) | Late 2030s (patents) |
| Pipeline successor | CagriSema, oral semaglutide 25/50 mg | Retatrutide, orforglipron |
For the full pipeline tracker, see our pharma desk and the semaglutide vs tirzepatide vs retatrutide long-form guide.